RADIOPHARM THERANOSTICS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.029 AUD | -3.33% |
|
-9.38% | -60.81% |
| May. 08 | Radiopharm Theranostics to be Featured in Healthcare Events Hosted by B. Riley Securities | MT |
| Feb. 29 | Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study | MT |
Valuation
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 26.42 | 23.73 | 9.2 | - | - |
| Enterprise Value (EV) 1 | 26.42 | 23.73 | 14.48 | 13.16 | 12.5 |
| P/E ratio | -0.9 x | -0.95 x | -0.29 x | -0.29 x | -0.3 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 125 x | 143 x | - | 3.45 x |
| EV / Revenue | - | 125 x | 225 x | - | 4.69 x |
| EV / EBITDA | -2.14 x | -1.17 x | -0.51 x | -0.4 x | -0.34 x |
| EV / FCF | - | -1.48 x | 1.82 x | -0.69 x | -0.91 x |
| FCF Yield | - | -67.5% | 54.8% | -145% | -110% |
| Price to Book | - | 0.83 x | - | - | - |
| Nbr of stocks (in thousands) | 255,433 | 339,313 | 460,367 | - | - |
| Reference price 2 | 0.1034 | 0.0699 | 0.0200 | 0.0200 | 0.0200 |
| Announcement Date | 8/30/22 | 8/31/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 0.1893 | 0.0645 | - | 2.663 |
| EBITDA 1 | - | -12.36 | -20.19 | -28.38 | -32.76 | -36.58 |
| EBIT 1 | - | -14.42 | -22.33 | -23.62 | -27.78 | -29.41 |
| Operating Margin | - | - | -11,796.17% | -36,627.45% | - | -1,104.34% |
| Earnings before Tax (EBT) 1 | - | -20.85 | -22.38 | -29.11 | -31.87 | -37.13 |
| Net income 1 | -0.3503 | -20.88 | -22.41 | -29.11 | -31.87 | -37.13 |
| Net margin | - | - | -11,838.62% | -45,144.93% | - | -1,394.38% |
| EPS 2 | - | -0.1152 | -0.0733 | -0.0695 | -0.0695 | -0.0660 |
| Free Cash Flow 1 | - | - | -16.01 | 7.94 | -19.03 | -13.69 |
| FCF margin | - | - | -8,459.64% | 12,313.68% | - | -514.08% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/23/21 | 8/30/22 | 8/31/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 S2 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.1013 | 0.0945 | 0.1974 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | -14.55 | - | -3.285 | -3.302 | -4.99 | -5.007 | -4.773 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | -8.476 | -14.28 | - | - | - | - | - | - |
| Net margin | - | - | -4,293.45% | - | - | - | - | - | - | - |
| EPS | - | - | -0.0307 | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/28/22 | 2/28/23 | 2/28/23 | 8/31/23 | 2/29/24 | - | - | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 5.28 | 3.96 | 3.3 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | -0.1859 x | -0.1208 x | -0.0902 x |
| Free Cash Flow 1 | - | - | -16 | 7.94 | -19 | -13.7 |
| ROE (net income / shareholders' equity) | - | - | - | -120% | -127% | -132% |
| ROA (Net income/ Total Assets) | - | - | - | -64.5% | -70.7% | -75.2% |
| Assets 1 | - | - | - | 45.13 | 45.07 | 49.38 |
| Book Value Per Share | - | - | 0.0800 | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | - | 0.99 | 0.03 | 0.03 | 0.03 |
| Capex / Sales | - | - | 523.56% | 51.18% | - | 1.24% |
| Announcement Date | 11/23/21 | 8/30/22 | 8/31/23 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.02
USD
Average target price
0.252
USD
Spread / Average Target
+1,161.01%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -60.81% | 9.17M | |
| +43.64% | 749B | |
| +39.42% | 605B | |
| -6.58% | 351B | |
| +19.72% | 328B | |
| +8.78% | 292B | |
| +11.92% | 216B | |
| -2.62% | 214B | |
| +0.03% | 167B | |
| +6.13% | 165B |
- Stock Market
- Equities
- RAD Stock
- Financials Radiopharm Theranostics Limited
